Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
125,684,656
-
Total 13F shares
-
97,643,165
-
Share change
-
+138,394
-
Total reported value
-
$6,665,378,163
-
Put/Call ratio
-
213%
-
Price per share
-
$68.30
-
Number of holders
-
245
-
Value change
-
+$32,228,664
-
Number of buys
-
153
-
Number of sells
-
91
Institutional Holders of Apellis Pharmaceuticals, Inc. - Common Stock, $0.0001 par value (APLS) as of Q3 2022
As of 30 Sep 2022,
Apellis Pharmaceuticals, Inc. - Common Stock, $0.0001 par value (APLS) was held by
245 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
97,643,165 shares.
The largest 10 holders included
Avoro Capital Advisors LLC, WELLINGTON MANAGEMENT GROUP LLP, VANGUARD GROUP INC, BlackRock Inc., T. Rowe Price Investment Management, Inc., EcoR1 Capital, LLC, PRICE T ROWE ASSOCIATES INC /MD/, STATE STREET CORP, JENNISON ASSOCIATES LLC, and Octagon Capital Advisors LP.
This page lists
245
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.